Evidence — TB-500 / TB4
peptide · asset evidence level: emerging
Evidence quality breakdown (linked documents)
expert_opinion: 2preclinical: 1
Linked source documents (3)
- Integrative Peptide Therapy — Clinical Reference Protocol (Demo Import) (physician_protocol · expert_opinion)
- Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model.docx (physician_protocol · expert_opinion)
- TB-500 / TB4: Mechanistic Overview (internal_protocol · preclinical)
Provider dosing references (Stage 9, source-attributed)
2-2.5 mg SC twice weekly (loading 4-6 weeks), then 2 mg weekly maintenance — Practitioner Peptide Dosing Reference (commonly published ranges)
Dosing claims (6) · Safety claims (4)
Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.